Sign In
Section Navigation
Common TitleCALIBRATE
Official Title A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Phase Phase II
ClinicalTrials.gov NCT04143594
Treatments
Lenacapavir

Lenacapavir

Class:Capsid Inhibitors
Categories Treatment-NaiveDual Therapy
Funding
IndustryGilead Sciences
References
  • Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023;10:e15-e23.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.